QuidelOrtho Appoints Micah Young as Chief Financial Officer
Rhea-AI Summary
QuidelOrtho (Nasdaq: QDEL) appointed Micah Young as Chief Financial Officer, effective July 6, 2026, succeeding retiring CFO Joseph M. Busky, who will serve in an advisory role to support transition.
Young brings over two decades of medical technology finance leadership at global public companies.
Positive
- Experienced medical technology finance leader appointed CFO effective July 6, 2026
- Orderly CFO succession with outgoing CFO remaining as advisor during transition
- Background includes CFO role at Masimo and senior finance roles at major medtech firms
Negative
- CFO retirement introduces leadership transition in a key financial role
News Market Reaction – QDEL
In the Jun 23 session, QDEL declined 3.52%, reflecting a moderate negative market reaction. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 02 | Strategic collaboration | Positive | +0.1% | Collaboration to improve education and early testing in alloimmunized pregnancies. |
| May 21 | Educational podcast | Neutral | +4.0% | Science podcast episode on HDFN awareness and lab testing in pregnancy care. |
| May 20 | Investor conferences | Neutral | +3.8% | Announcement of participation in June investor conferences and webcast availability. |
| May 05 | Quarterly earnings | Negative | -6.0% | Q1 2026 results with GAAP loss and guidance reflecting external market uncertainties. |
| Apr 23 | Disease trend podcast | Neutral | -5.5% | Podcast on U.S. syphilis trends and missed prenatal screening opportunities. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent QDEL headlines have usually seen price moves align with the news tone, with one notable downside move on neutral content.
Key Terms
certified public accountant financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Seasoned medical technology finance executive brings more than two decades of leadership at global public companies
"Micah is an accomplished public-company CFO with deep medical technology expertise and a strong track record of improving financial performance, strengthening cash flow and driving disciplined execution," said Brian J. Blaser, President and Chief Executive Officer of QuidelOrtho. "His leadership across business strategy, capital allocation, investor relations and financial operations will be valuable as we execute our priorities to improve profitability, enhance cash generation and create long-term shareholder value. We are excited to welcome Micah to the QuidelOrtho leadership team."
Mr. Blaser added, "We thank Joe for his leadership and many contributions to QuidelOrtho. He has played an important role in strengthening our financial discipline and guiding the Company through a period of significant transformation. We appreciate his support of a seamless transition and wish him the very best."
Mr. Young most recently served as Executive Vice President and Chief Financial Officer of Masimo Corporation, a global medical technology company. He joined Masimo as CFO in 2017 and helped lead the company through a period of strategic transformation, operational improvement, disciplined capital allocation, enhanced investor engagement and significant transaction activity. Previously, he held progressively senior finance roles at NuVasive, Inc. and finance and accounting roles at Zimmer Holdings, Inc., after beginning his career at Deloitte & Touche LLP. Mr. Young holds a Bachelor of Science in Accounting and Criminal Justice from Indiana Wesleyan University and is a Certified Public Accountant (inactive).
"I am honored to join QuidelOrtho at an important point in the Company's evolution," said Mr. Young. "QuidelOrtho has a strong global portfolio, a meaningful mission and clear opportunities to enhance execution and performance. I look forward to working with Brian, the Board and the leadership team to strengthen operational discipline, support growth and create sustainable value for shareholders, customers and patients."
QuidelOrtho is dedicated to advancing diagnostics to power a healthier future. For more information, please visit quidelortho.com and follow QuidelOrtho on LinkedIn, Facebook and X.
About QuidelOrtho Corporation
With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, dedicated to advancing fast, accurate and reliable results that help improve patient outcomes – from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.
Investor Contact:
Juliet Cunningham
Vice President, Investor Relations
IR@QuidelOrtho.com
Media Contact:
Stephanie Kleewein
Senior Corporate Communications and PR Manager
media@QuidelOrtho.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/quidelortho-appoints-micah-young-as-chief-financial-officer-302807156.html
SOURCE QuidelOrtho Corporation